ALK and neuroblastoma: In neuroblastoma and neuroendocrine prostate cancer, activation of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase up-regulates MYCN transcription through a STAT3-dependent mechanism (44–46).